Cargando…

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions

Nitric oxide (NO) is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis. Inhibition of NO synthase by L-NAME might induce an anti-tumour effect by limiting nutrients and oxygen to reach tumour tissue or affecting vascular growth. The anti-tumour effect of L-NAM...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wilt, J H W, Manusama, E R, van Etten, B, van Tiel, S T, Jorna, A S, Seynhaeve, A L B, ten Hagen, T L M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363576/ https://www.ncbi.nlm.nih.gov/pubmed/11027431 http://dx.doi.org/10.1054/bjoc.2000.1447

Ejemplares similares

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
por: Seynhaeve, A L B, et al.
Publicado: (2002)

TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
por: van der Veen, A H, et al.
Publicado: (2000)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats
por: Veen, A H van der, et al.
Publicado: (1999)

Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion
por: van Etten, B, et al.
Publicado: (2003)

Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
por: Nooijen, P. T., et al.
Publicado: (1996)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors
por: van Etten, B, et al.
Publicado: (2004)

Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.
por: Marinelli, A., et al.
Publicado: (1991)

Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis
por: Fenton, B M, et al.
Publicado: (2002)

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
por: Kuppen, P. J., et al.
Publicado: (1997)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

Effect of mast cell granules on the gene expression of nitric oxide synthase and tumour necrosis factor-alpha in macrophages.
por: Li, Y, et al.
Publicado: (1998)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation
por: van Ginkel, Robert J., et al.
Publicado: (2007)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
por: Sheldon, P. W., et al.
Publicado: (1982)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase
por: Berge, D L Van den, et al.
Publicado: (2001)

Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts.
por: Wist, E., et al.
Publicado: (1981)

Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
por: Horsman, M. R., et al.
Publicado: (1984)

Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer
por: van der Zee, J A, et al.
Publicado: (2012)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Use of thymidine analogues to indicate vascular perfusion in tumours
por: Begg, A C, et al.
Publicado: (2000)

Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour.
por: Miller, B. E., et al.
Publicado: (1993)

Influence of anaesthetics on tumour-cell kill and repopulation in B16 melanoma treated with melphalan.
por: Peacock, J. H., et al.
Publicado: (1978)

The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
por: McNally, N. J.
Publicado: (1982)

17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response
por: Chinje, E C, et al.
Publicado: (2002)

Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth
por: Barbieri, Antonio, et al.
Publicado: (2012)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
por: Borel Rinkes, I. H., et al.
Publicado: (1997)

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tffp1megflkg0hfj1a3g16fsgu